Related Experiment Video
Updated: Apr 30, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.8K
Compliance after switching from branded to generic statins
Robert J Romanelli1, Trevor Jukes, Jodi B Segal
1Clinical Outcomes Research Group, Clinical Integration Department, Sutter Health, Sacramento, CA, USA; Palo Alto Medical Foundation Research Institute, Palo Alto, CA, USA.
Pharmacoepidemiology and Drug Safety
|May 13, 2014
Summary
Switching to generic statins generally maintained medication compliance compared to branded statins. However, therapeutic substitutions, unlike generic substitutions, showed initial lower compliance that improved over time.
Area of Science:
- Cardiovascular Medicine
- Pharmacoeconomics
- Health Services Research
Background:
- Generic statin substitution is common practice to reduce healthcare costs.
- Understanding the impact of these switches on patient adherence is crucial for effective cardiovascular disease management.
Purpose of the Study:
- To evaluate the effect of switching from branded to generic statins on patient medication compliance.
- To compare compliance rates between patients who switched to generic statins and those who continued branded statins.
Main Methods:
- A historic cohort study utilized electronic health records to identify patients on branded statins.
- Patients were classified as switchers or non-switchers and matched using propensity scores.
- Medication Possession Ratio (MPR) was calculated to assess compliance (MPR ≥ 0.80).
Main Results:
- Overall compliance with statin therapy was similar between switchers and non-switchers.
- Patients switching to a generic statin of a different agent (therapeutic substitution) initially showed lower compliance than those switching to the same agent (generic substitution).
- Compliance improved significantly for therapeutic substitutions after 12 months compared to generic substitutions.
Conclusions:
- Medication compliance with statin therapy is largely comparable between patients switching to generic versions and those staying on branded medications.
- Reviewing statin dosing is recommended during therapy changes to ensure optimal clinical outcomes and patient adherence.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
420
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
420
01:13Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
01:26FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K